Articles From: CYS Investments, Inc. Announces Fourth Quarter and Year Ended 2013 Financial Results to Cytori’s Celution® System Approved in Australia for Processing and Delivering Adipose-Derived Regenerative Cells


2014/2/10
CYS Investments, Inc. (NYSE: CYS) (“CYS” or the “Company”) today announced financial results for the quarter and year ended December 31, 2013.
Sign-up for CYS Investments, Inc. Announces Fourth Quarter and Year Ended 2013 Financial Results investment picks
2014/2/7
CYS Investments, Inc. (NYSE: CYS) (the "Company") announced today that its Board of Directors has established March 7, 2014, as the record date for determining stockholders entitled to vote at the 2014 Annual Meeting of Stockholders.
Sign-up for CYS Investments, Inc. Announces Record and Meeting Dates for 2014 Annual Meeting of Stockholders investment picks
2013/10/16
CYS Investments, Inc. (NYSE: CYS) (“CYS” or the “Company”) today announced financial results for the quarter ended September 30, 2013.
Sign-up for CYS Investments, Inc. Announces Third Quarter 2013 Financial Results investment picks
2014/3/10
The Board of Directors of CYS Investments, Inc. (NYSE: CYS) (the "Company") today declared a quarterly dividend of $0.32 per share of common stock for the first quarter of 2014.
Sign-up for CYS Investments, Inc. Board of Directors Declares First Quarter 2014 Common Stock Dividend of $0.32 Per Share, and Preferred Stock Dividends investment picks
The Board of Directors of CYS Investments, Inc. (NYSE: CYS) (the "Company") today declared a quarterly dividend of $0.32 per share of common stock for the fourth quarter of 2013.
Sign-up for CYS Investments, Inc. Board of Directors Declares Fourth Quarter 2013 Common Stock Dividend of $0.32 Per Share, and Preferred Stock Dividends investment picks
2014/1/9
CYS Investments, Inc. (NYSE: CYS) ("CYS" or the "Company") today announced that it will host the 2014 CYS Analyst and Investor Day on Monday, April 28, 2014, from 9:00 a.m. to 1:30 p.m. in Boston, Massachusetts.
Sign-up for CYS Investments, Inc. to Host 2014 Analyst and Investor Day investment picks
CYS Investments, Inc. (NYSE: CYS) ("CYS" or the "Company") today announced that Kevin E.
Sign-up for CYS Investments, Inc. to Present at Barclays Global Financial Services Conference investment picks
CYS Investments, Inc. (NYSE: CYS) (the "Company") today announced that Kevin E.
Sign-up for CYS Investments, Inc. to Present at RBC Capital Markets' Financial Institutions Conference investment picks
CYS Investments, Inc. (NYSE: CYS) ("CYS" or the "Company") today announced that Kevin E.
Sign-up for CYS Investments, Inc. to Present at the Bank of America Merrill Lynch Banking & Financial Services Conference investment picks
2014/1/13
http://media.marketwire.com/attachments/201401/215299_671-1-m.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1081219&ProfileId=051205&sourceType=1 ORLANDO, FL and CHICAGO, IL --
Sign-up for CytoCore to Acquire MEDITE investment picks
2014/1/9
CytomX Therapeutics , the Probody™ therapeutics company, and ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its validated, industry-leading antibody-drug conjugate (ADC) technology, today announced a multi-year, strategic collaboration to develop Probody-drug conjugate (PDC) therapies for the treatment of cancer.
Sign-up for CytomX Therapeutics and ImmunoGen, Inc. Announce Strategic Collaboration to Develop Probody-Drug Conjugates Against Cancer Targets investment picks
2014/1/7
Cytori Therapeutics, Inc. (NASDAQ:CYTX) will webcast their corporate presentation at the Biotech Showcase ™ at 11:00 AM PT (2:00 PM ET) on Monday, January 13.
Sign-up for Cytori Announces Presentation at Biotech Showcase™ on January 13 investment picks
2014/4/2
Cytori Therapeutics (NASDAQ: CYTX) today announced that Christopher Calhoun, Chief Executive Officer and Director of Cytori Therapeutics, is retiring from the position of CEO of the Company, effective immediately.
Sign-up for Cytori Announces Senior Management Changes investment picks
2013/11/21
Cytori Therapeutics (NASDAQ: CYTX) reports that on November 20, 2013, the Japanese legislature (Diet) approved new legislation targeted at regenerative medicine therapies.
Sign-up for Cytori Comments on New Legislation for Regenerative Medicine in Japan investment picks
2013/7/31
Cytori Therapeutics (NASDAQ: CYTX) has entered into a $15 million three-part agreement with Bimini Technologies and its affiliates, Puregraft Technologies and Kerastem Technologies.
Sign-up for Cytori Divests Puregraft® Products, Licenses Celution® for Alopecia and Options Broader Aesthetic Market Rights investment picks
Cytori Therapeutics (NASDAQ:CYTX) has received approval from the Health Sciences Authority (HSA) in Singapore for the Celution® System for autologous re-implantation or re-infusion of a patient’s own adipose-derived regenerative cells (ADRCs). The Celution® System enables access to a patient’s own ADRCs at the point-of-care for a range of injuries and conditions.
Sign-up for Cytori Obtains Celution® System Approval in Singapore investment picks
2013/10/10
Cytori Therapeutics (NASDAQ:CYTX) has received an Australian patent covering methods of treating cardiovascular disease using adipose-derived regenerative cells (ADRCs). The patent covers the therapeutic use of ADRCs for improving cardiac function and mechanics by preventing the deleterious histopathological and structural changes that occur in the heart following a heart attack (cardiac remodeling). “This patent expands our growing body of global patents surrounding therapeutic uses for our Celution® cell output,” said Christopher Calhoun, CEO of Cytori.
Sign-up for Cytori Patents Adipose-Derived Cell Therapy for Cardiovascular Disease in Australia investment picks
Cytori Therapeutics (NASDAQ: CYTX) has received the first $12 million installment from the equity agreement with newly formed Lorem Vascular.
Sign-up for Cytori Receives $12 Million for the First Installment from the Lorem Vascular Partnership Equity Agreement investment picks
Cytori Therapeutics (NASDAQ: CYTX) today reports its second quarter 2013 financial results and provides updates on clinical development and commercialization activities.
Sign-up for Cytori Reports First Half and 2nd Quarter 2013 Business and Financial Results investment picks
2014/3/11
Cytori Therapeutics (NASDAQ: CYTX) reports its fourth quarter and year end 2013 business and financial results and provides an outlook for 2014.
Sign-up for Cytori Reports Fourth Quarter and Full Year 2013 Business and Financial Results investment picks
Cytori Therapeutics (NASDAQ: CYTX) today reports its nine month and third quarter 2013 financial results and provides updates on clinical development, commercialization and corporate development activities.
Sign-up for Cytori Reports Nine Month and Third Quarter 2013 Business and Financial Results investment picks
2013/10/8
Cytori Therapeutics, Inc. (NASDAQ: CYTX) will give a company presentation at the 3 rd Annual Regen Med Partnering Forum , part of the 2013 Stem Cell Meeting on the Mesa on Tuesday, October 15.
Sign-up for Cytori Therapeutics Announces Participation at the 2013 Stem Cell Meeting on the Mesa’s 3rd Annual Regen Med Partnering Forum on October 14th and 15th investment picks
2014/3/20
Cytori Therapeutics (NASDAQ: CYTX) will present at the 2 nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City.
Sign-up for Cytori Therapeutics to Present at Regen Med Investor Day March 26 in New York investment picks
2014/3/6
Cytori Therapeutics, Inc. (NASDAQ:CYTX) will present and provide a corporate update from the 26 th Annual Roth Conference on Wednesday, March 12, at 10:30 AM PT.
Sign-up for Cytori Therapeutics to Present at the 26th Annual Roth Conference on March 12 investment picks
Cytori Therapeutics Inc. (NASDAQ: CYTX) will present and provide a corporate update from the LD Micro Conference on Thursday, December 5, at 4:30 PM PT.
Sign-up for Cytori Therapeutics to Present at the LD Micro Conference on December 5 investment picks
2014/1/13
Cytori Therapeutics (NASDAQ:CYTX) has received Investigational Device Exemption (IDE) approval from the FDA to begin a prospective clinical trial to evaluate the safety and feasibility of Cytori Cell Therapy as a potential treatment for hamstring injuries.
Sign-up for Cytori to Initiate U.S. Clinical Trial of Adipose-Derived Regenerative Cells in Hamstring Injuries investment picks
2014/3/4
Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its fourth quarter and year end financial results and business update on Tuesday, March 11, 2014 at 5:00 PM Eastern Time.
Sign-up for Cytori to Webcast Fourth Quarter and Year End Financial Results on March 11 investment picks
Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its second quarter financial results and business update on Thursday, August 8, 2013 at 5:00 PM Eastern Time.
Sign-up for Cytori to Webcast Second Quarter Financial Results on August 8 investment picks
2013/11/1
Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its third quarter financial results and business update on Thursday, November 7, 2013 at 5:00 PM Eastern Time.
Sign-up for Cytori to Webcast Third Quarter Financial Results on November 7 investment picks
2013/8/7
Cytori Therapeutics (NASDAQ: CYTX) has received notice from the Australian Therapeutic Goods Administration (TGA) that the Celution® System is approved for commercial use through inclusion on the Australian Registry of Therapeutic Goods for autologous re-implantation or re-infusion of a patient’s adipose-derived regenerative cells (ADRCs). The Celution® System produces autologous (a patient’s own) ADRCs at the point-of-care which may then be used for a range of injuries or conditions.
Sign-up for Cytori’s Celution® System Approved in Australia for Processing and Delivering Adipose-Derived Regenerative Cells investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: CYS Investments, Inc. Announces Fourth Quarter and Year Ended 2013 Financial Results to Cytori’s Celution® System Approved in Australia for Processing and Delivering Adipose-Derived Regenerative Cells
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity